198 related articles for article (PubMed ID: 37909894)
21. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
22. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
Braun J; Kiltz U; Baraliakos X
Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients.
Mahmoud AM
Curr Med Res Opin; 2023 Jul; 39(7):1031-1043. PubMed ID: 37345857
[TBL] [Abstract][Full Text] [Related]
24. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies.
Sánchez-Rodríguez G; Puig L
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373452
[TBL] [Abstract][Full Text] [Related]
25. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
26. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.
Camiña-Conforto G; Mateu-Arrom L; López-Ferrer A; Puig L
Patient Prefer Adherence; 2023; 17():1541-1549. PubMed ID: 37408843
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis.
Su QY; Yang L; Cao TY; Dang HY; Han ZC; Cao JJ; Zhang HY; Cheng T; Zhang SX; Huo YH
Expert Opin Drug Saf; 2024 Apr; ():1-9. PubMed ID: 38646719
[TBL] [Abstract][Full Text] [Related]
28. Bimekizumab for Moderate-to-Severe Plaque Psoriasis.
Gotesman RD; Vender R
Skin Therapy Lett; 2021 May; 26(3):1-4. PubMed ID: 34077151
[TBL] [Abstract][Full Text] [Related]
29. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
30. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
Coates LC; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Orbai AM; Gottlieb AB; Warren RB; Ink B; Bajracharya R; Shende V; Coarse J; Merola JF
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38388171
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.
Hagino T; Saeki H; Fujimoto E; Kanda N
J Dermatol; 2024 May; 51(5):649-658. PubMed ID: 38482898
[TBL] [Abstract][Full Text] [Related]
32. Dual inhibition of IL-17A and IL-17F in psoriatic disease.
Iznardo H; Puig L
Ther Adv Chronic Dis; 2021; 12():20406223211037846. PubMed ID: 34408825
[TBL] [Abstract][Full Text] [Related]
33. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
[TBL] [Abstract][Full Text] [Related]
34. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
Blauvelt A; Armstrong A; Merola JF; Strober B; de Cuyper D; Peterson L; Davies O; Stark JL; Lebwohl M
J Am Acad Dermatol; 2024 Jul; 91(1):72-81. PubMed ID: 38447700
[TBL] [Abstract][Full Text] [Related]
35. Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
[TBL] [Abstract][Full Text] [Related]
36. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
[TBL] [Abstract][Full Text] [Related]
37. Bimekizumab: the new drug in the biologics armamentarium for psoriasis.
Freitas E; Torres T
Drugs Context; 2021; 10():. PubMed ID: 34178093
[TBL] [Abstract][Full Text] [Related]
38. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
39. The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy.
Kokolakis G; Ghoreschi K
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614836
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
